Benjamin Kaffenberger, MD, MS, FAAD
SESSIONS
F043 New Drugs, New Rashes: An Update on Cutaneous Drug Eruptions
Mar 28, 2026
•
3:30 PM - 5:30 PM
•
Room 301
F092 The Morbilliform Eruption: Differentiation and Treatment of Viral, Low-Risk Drug, Severe Cutaneous Adverse Reactions, and GVHD
Mar 30, 2026
•
1:00 PM - 3:00 PM
•
Mile High 1A
DISCLOSURES
Almirall – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant (1099 relationship)(Honoraria); HCW Biologics – Investigator(Grants/Research Funding); InflaRx – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); Leo Pharma – Investigator(Grants/Research Funding); National Comprehensive Cancer Network – Speaker(Honoraria);